Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Jiricek

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|October 5, 2013
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agentsRavinder Reddy Kondreddi, Jan Jiricek, Srinivasa P S Rao, et al.
Journal of Medicinal Chemistry|July 16, 2011
Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824)Joseph Cherian, Inhee Choi, Amit Nayyar, et al.
Journal of Medicinal Chemistry|January 7, 2026
Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of <i>Trypanosoma cruzi</i> Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection ModelOlivier René, Manuel Saldivia, Maxime Dauphinais, et al.
Nature Microbiology|July 15, 2020
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitorsManuel Saldivia, Eric Fang, Xiaolei Ma, et al.
Journal of Medicinal Chemistry|August 22, 2022
Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)Dennis C Koester, Vanessa M Marx, Sarah Williams, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agentsFumiaki Yokokawa, Gang Wang, Wai Ling Chan, et al.
Science Translational Medicine|December 6, 2013
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosisSrinivasa P S Rao, Suresh B Lakshminarayana, Ravinder R Kondreddi, et al.
Nature Communications|October 27, 2010
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacyKevin Pethe, Patricia C Sequeira, Sanjay Agarwalla, et al.
Journal of Medicinal Chemistry|July 16, 2020
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of LeishmaniasesAdvait Nagle, Agnes Biggart, Celine Be, et al.
Science (New York, N.Y.)|June 29, 2023
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infectionsSrinivasa P S Rao, Matthew K Gould, Jonas Noeske, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|October 5, 2013
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agentsRavinder Reddy Kondreddi, Jan Jiricek, Srinivasa P S Rao, et al.
Journal of Medicinal Chemistry|July 16, 2011
Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824)Joseph Cherian, Inhee Choi, Amit Nayyar, et al.
Journal of Medicinal Chemistry|January 7, 2026
Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of <i>Trypanosoma cruzi</i> Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection ModelOlivier René, Manuel Saldivia, Maxime Dauphinais, et al.
Nature Microbiology|July 15, 2020
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitorsManuel Saldivia, Eric Fang, Xiaolei Ma, et al.
Journal of Medicinal Chemistry|August 22, 2022
Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)Dennis C Koester, Vanessa M Marx, Sarah Williams, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agentsFumiaki Yokokawa, Gang Wang, Wai Ling Chan, et al.
Science Translational Medicine|December 6, 2013
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosisSrinivasa P S Rao, Suresh B Lakshminarayana, Ravinder R Kondreddi, et al.
Nature Communications|October 27, 2010
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacyKevin Pethe, Patricia C Sequeira, Sanjay Agarwalla, et al.
Journal of Medicinal Chemistry|July 16, 2020
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of LeishmaniasesAdvait Nagle, Agnes Biggart, Celine Be, et al.
Science (New York, N.Y.)|June 29, 2023
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infectionsSrinivasa P S Rao, Matthew K Gould, Jonas Noeske, et al.
Pageof 3